Haemonetics elects Martin Madaus to board; shareholders approve equity plan changes
Haemonetics' board elected Martin Madaus, a Carlyle Group Senior Operating Executive, as a director effective July 24, 2026. At the same meeting, shareholders re-elected eight directors, approved an advisory say-on-pay vote, ratified Ernst & Young LLP as auditor, and approved amended 2019 Long-Term Incentive Compensation and 2007 Employee Stock Purchase Plans. The plan changes authorize 4,680,000 additional shares under the incentive plan and extend both plans through 2036.
Key points
- Martin Madaus elected director effective July 24, 2026; expected to join the Audit Committee and Governance and Compliance Committee
- Non-employee director annual equity award with an approximate value of $200,000
- Shareholders approved the incentive plan amendment, which authorizes 4,680,000 additional shares, with 37,730,923 votes for and 2,055,726 against
- Ellen Zane, Christopher Simon and six other nominees re-elected for one-year terms expiring in 2027
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.